Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting
Ran Salomon, Hagar Rotem, Yonatan Katzenelenbogen, et al.
Nature Cancer (2022) Vol. 3, Iss. 3, pp. 287-302
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Macrophages at the interface of the co-evolving cancer ecosystem
Daan J. Kloosterman, Leila Akkari
Cell (2023) Vol. 186, Iss. 8, pp. 1627-1651
Open Access | Times Cited: 183
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Miguel Á. Galán, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 257-277
Closed Access | Times Cited: 105
Dendritic cells as shepherds of T cell immunity in cancer
Mikaël J. Pittet, Mauro Di Pilato, Christopher Garris, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2218-2230
Open Access | Times Cited: 92
Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target
Jiaxin Li, Jun Zhou, Huanhuan Huang, et al.
Clinical and Translational Medicine (2023) Vol. 13, Iss. 2
Open Access | Times Cited: 48
Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy
Yuebao Zhang, Xucheng Hou, Shi Du, et al.
Nature Nanotechnology (2023) Vol. 18, Iss. 11, pp. 1364-1374
Closed Access | Times Cited: 48
Bispecific dendritic-T cell engager potentiates anti-tumor immunity
Y Itai, Oren Barboy, Ran Salomon, et al.
Cell (2024) Vol. 187, Iss. 2, pp. 375-389.e18
Open Access | Times Cited: 45
Radiotherapy and immunology
Liangliang Wang, Connor Lynch, Sean P. Pitroda, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 7
Open Access | Times Cited: 27
Cross-priming in cancer immunology and immunotherapy
Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 3
Dendritic cell maturation in cancer
Chang Moon, Meriem Belabed, Matthew D. Park, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 2
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Ran Salomon, Rony Dahan
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Glycolysis drives STING signaling to facilitate dendritic cell antitumor function
Zhilin Hu, Xiaoyan Yu, Rui Ding, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 41
Fcγ receptors and immunomodulatory antibodies in cancer
Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, et al.
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 51-71
Closed Access | Times Cited: 29
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, et al.
Science Immunology (2023) Vol. 8, Iss. 81
Closed Access | Times Cited: 27
Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols
Oren Barboy, Akhiad Bercovich, Hanjie Li, et al.
Nature Cancer (2024) Vol. 5, Iss. 5, pp. 742-759
Closed Access | Times Cited: 13
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
Jie Chen, Yu-Hang Duan, Junye Che, et al.
Cancer Communications (2024) Vol. 44, Iss. 9, pp. 1047-1070
Open Access | Times Cited: 10
A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies
Cheng-Zhe Jian, Lin Li, Chia‐Lang Hsu, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103893-103893
Closed Access | Times Cited: 9
Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison
Linyan Cheng, Lujun Chen, Yuan Shi, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Harnessing the potential of CD40 agonism in cancer therapy
Yang Zhou, Ann Richmond, Chi Yan
Cytokine & Growth Factor Reviews (2023) Vol. 75, pp. 40-56
Open Access | Times Cited: 16
Genetically engineered membrane-based nanoengagers for immunotherapy of pancreatic cancer
Haoqi Zhang, Yuanke Li, Helong Kang, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Spatial characterization and quantification of CD40 expression across cancer types
Katherine M. Bates, Ioannis Vathiotis, Tyler MacNeil, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Next generation CD40 agonists for cancer immunotherapy
Hampus Andersson, Barnabas Nyesiga, Tova Hermodsson, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 351-363
Open Access | Times Cited: 4
Recent developments in myeloid immune modulation in cancer therapy
Sepideh Parvanian, Xinying Ge, Christopher Garris
Trends in cancer (2025)
Closed Access
A bioengineered antibody conjugate reshape dendritic cell viability for immune-tolerance modulation
Xiaohong Chen, Yalin Wang, Tao Xu, et al.
Chemical Engineering Journal (2025), pp. 160431-160431
Closed Access
Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy
R R Zhao, Xing-Xing Fan
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1440-1440
Open Access
Page 1 - Next Page

Scroll to top